Xu, M., Weng, H., & Dooley, S. (2016). Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B. BioMed Central.
Chicago Style (17th ed.) CitationXu, Ming-Yi, Honglei Weng, and Steven Dooley. Serum Dihydroxyacetone Kinase Peptide M/z 520.3 as Predictor of Disease Severity in Patients with Compensated Chronic Hepatitis B. London: BioMed Central, 2016.
MLA (9th ed.) CitationXu, Ming-Yi, et al. Serum Dihydroxyacetone Kinase Peptide M/z 520.3 as Predictor of Disease Severity in Patients with Compensated Chronic Hepatitis B. BioMed Central, 2016.
Warning: These citations may not always be 100% accurate.